FIL Ltd held its position in shares of NxStage Medical, Inc. (NASDAQ:NXTM) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 148,452 shares of the medical device company’s stock at the end of the 2nd quarter. FIL Ltd owned about 0.23% of NxStage Medical worth $3,722,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. SG Americas Securities LLC bought a new stake in shares of NxStage Medical during the first quarter worth about $140,000. Ameritas Investment Partners Inc. bought a new stake in shares of NxStage Medical during the first quarter worth about $148,000. Menta Capital LLC bought a new stake in shares of NxStage Medical during the first quarter worth about $212,000. Jane Street Group LLC bought a new stake in shares of NxStage Medical during the first quarter worth about $213,000. Finally, PEAK6 Investments L.P. bought a new stake in shares of NxStage Medical during the first quarter worth about $214,000. 92.75% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/28/nxstage-medical-inc-nxtm-position-maintained-by-fil-ltd.html.

In other NxStage Medical news, President Joseph E. Turk, Jr. sold 24,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $29.64, for a total transaction of $711,360.00. Following the completion of the sale, the president now directly owns 82,903 shares in the company, valued at approximately $2,457,244.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Matthew W. Towse sold 4,300 shares of the firm’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $24.16, for a total transaction of $103,888.00. Following the sale, the senior vice president now owns 28,721 shares of the company’s stock, valued at $693,899.36. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,400 shares of company stock valued at $1,403,650. 4.70% of the stock is owned by company insiders.

Several research firms have recently commented on NXTM. Leerink Swann downgraded shares of NxStage Medical from an “outperform” rating to a “market perform” rating and boosted their target price for the stock from $28.00 to $30.00 in a research report on Tuesday, August 22nd. BTIG Research downgraded shares of NxStage Medical from a “buy” rating to a “neutral” rating in a research report on Friday, August 11th. Zacks Investment Research downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Stephens downgraded shares of NxStage Medical from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $33.00 to $30.00 in a research report on Wednesday, August 9th. Finally, Jefferies Group LLC downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating and decreased their target price for the stock from $33.00 to $30.00 in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating and nine have issued a hold rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $30.25.

NxStage Medical, Inc. (NASDAQ NXTM) opened at 27.54 on Thursday. NxStage Medical, Inc. has a 12-month low of $20.45 and a 12-month high of $30.80. The company’s 50-day moving average is $27.80 and its 200 day moving average is $25.85. The stock’s market capitalization is $1.82 billion.

NxStage Medical (NASDAQ:NXTM) last released its quarterly earnings data on Monday, August 7th. The medical device company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03). The business had revenue of $92.20 million during the quarter, compared to analyst estimates of $96.47 million. NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. NxStage Medical’s revenue was up .0% compared to the same quarter last year. During the same period last year, the business earned ($0.03) EPS. On average, equities research analysts expect that NxStage Medical, Inc. will post ($0.05) earnings per share for the current fiscal year.

NxStage Medical Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Stock Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related stocks with our FREE daily email newsletter.